Korean drugmaker Samsung Biologics said on Thursday it plans to split its business into contract manufacturing and development companies, to help allay customer concerns about conflicts of interest.

Samsung Biologics splits biosimilar business to boost CDMO, investment flexibility. Published : May 22, 2025 - 14:44:12 Updated : May 22, 2025 - 15:16:28 ...

Samsung BioLogics spin-off to separate contract drug making, new growth drivers. By Hyunjoo Jin and Joyce Lee. May 22, 2025 1:35 AM UTC Updated May 22, 2025 Summary; Companies ...

Shares of Samsung Biologics Co. and its largest holder Samsung C&T Corp. were volatile after the Korean contract drug manufacturer announced a spin-off plan. Investors saw the plan — which will ...

Once the split is complete, Samsung Bio will hold 1.16 trillion Korean won (roughly $840 million) in capital versus the new company’s 622.1 billion won ($450 million), Seung Ho Ryu, EVP of ...

Samsung Biologics explained that the split will allow the company to concentrate resources on its CDMO business, which operates under a different revenue model compared to biosimilars.

The stock trading suspension of Samsung BioLogics starting Thursday seemed to wrap up a chapter in the yearslong brawl over alleged accounting fraud, apparently with the defeat of the biotech ...

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its latest business achievements and 2025 outlook at the 43rd J.P. Morgan ...

Samsung Biologics (KRX: 207940.KS), a global contract manufacturing and development organization (CDMO), today announced that it has received 'Leadership' status and an A- rating for water ...

Samsung Biologics acquires three ISO certificates, including for compliance management. Samsung Biologics inks $77M deal with U.S. pharmaceutical. Samsung Biologics opens San Francisco R&D center.

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its latest business achievements and 2025 outlook at the 43rd J.P. Morgan ...